{"product_id":"luciabro-abrocitinib","title":"LuciAbro (Abrocitinib)","description":"\u003ch2\u003eAbout Abrocitinib\u003c\/h2\u003e\u003cp\u003eAbrocitinib is a medication used for the treatment of atopic dermatitis (eczema).\u003csup id=\"cite_ref-Cibinqo_FDA_label_8-1\" class=\"reference\"\u003e\u003c\/sup\u003e It is a Janus kinase inhibitor .\u003c\/p\u003e\u003cp\u003eIn the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.\u003csup id=\"cite_ref-Cibinqo_EPAR_9-5\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003cp\u003eIn the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.\u003csup id=\"cite_ref-Cibinqo_FDA_label_8-4\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eAtopic Dermatitis\u003c\/h3\u003e\u003cp\u003eIndicated for refractory moderate-to-severe atopic dermatitis (AD) in patients aged ≥12 years whose disease is not adequately controlled with other systemic therapies, including biologics, or for whom those therapies are inadvisable\u003c\/p\u003e\u003cp\u003e100 mg PO qDay\u003c\/p\u003e\u003cp\u003eIf adequate response not achieved, consider increasing to 200 mg qDay\u003c\/p\u003e\u003cp\u003eDiscontinue if adequate response not achieved with 200 mg\/day\u003c\/p\u003e\u003cp\u003eUse lowest efficacious dose to maintain response\u003c\/p\u003e\u003cp\u003eUse with or without topical corticosteroids\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eCYP2C19 poor metabolizers or coadministration with strong CYP2C19 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e50 mg qDay initially; if adequate response not achieved, may increase to 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eDiscontinue if inadequate response after dosage increase\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eInfection\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIf serious or opportunistic infections develops, interrupt treatment until infection is controlled\u003c\/li\u003e\n\u003cli\u003eCarefully consider risks and benefits of treatment before reinitiating\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHematologic abnormalities\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePlatelet count \u0026lt;50,000\/mm\u003csup\u003e3\u003c\/sup\u003e: Discontinue therapy and monitor until platelet count \u0026gt;100,000\/mm\u003csup\u003e3\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003eAbsolute lymphocyte count (ALC) \u0026lt;500 cells\/mm\u003csup\u003e3\u003c\/sup\u003e: Interrupt therapy; may restart once ALC \u0026gt;500 cells\/mm\u003csup\u003e3\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003eAbsolute neutrophil count (ANC) \u0026lt;1000 cells\/mm\u003csup\u003e3\u003c\/sup\u003e: Interrupt therapy; may restart once ANC \u0026gt;1000 cells\/mm3\u003c\/li\u003e\n\u003cli\u003eHemoglobin (Hb) \u0026lt;8 g\/dL: Interrupt therapy; may restart once Hb \u0026gt;8 g\/dL\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (eGFR 60-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (eGFR 30-59 mL\/min): 50 mg qDay initially; may double dose if adequate response not achieved\u003c\/li\u003e\n\u003cli\u003eSevere or end-stage renal disease (eGFR \u0026lt;29 mL\/min): Not recommended\u003c\/li\u003e\n\u003cli\u003ePatients on renal replacement therapy: Not studied; not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh A or B): No dose adjustment required\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955735595,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-119.jpg?v=1787022240","url":"https:\/\/xomeds.com\/products\/luciabro-abrocitinib","provider":"XOMEDS","version":"1.0","type":"link"}